SITC Cancer Immunotherapy Guidelines - Non-Small Cell Lung Cancer (NSCLC)

On July 17, 2018, the SITC Cancer Immunotherapy Guidelines-Non-Small Cell Lung Cancer (NSCLC) Subcommittee published a consensus statement specific to the treatment of patients with NSCLC.

This consensus statement consists of evidence-based recommendations from experts in the field for the use and sequencing of immunotherapies including nivolumab, pembrolizumab, atezolizumab and durvalumab. The statement also provides recommendations concerning patient selection, toxicity management and clinical endpoints.

SITC Cancer Immunotherapy Guidelines – NSCLC Webinar

Learn more about immunotherapy treatment guidelines for non-small cell lung cancer. Hear about The Society for Immunotherapy of Cancer’s recently published consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) in this free session. SITC hosted this one-hour webinar on Thursday, Sept. 13, 2018.

Click here to view the webinar on-demand.

Current Guideline

UP-TO-DATE

Published July 17, 2018 in Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)"

Pocket Guides

Key points from SITC's Cancer Immunotherapy Guidelines have been distilled into Pocket Guides. These condensed, easily accessible versions of the full Cancer Immunotherapy Guidelines are a quick-reference tool available in both digital and print.

Download SITC's Cancer Immunotherapy Pocket Guides on any desktop or mobile device free today.*

*Available only through the Guideline Central App.

ORDER Digital/Print Guides

SITC Cancer Immunotherapy Guidelines Non-Small Cell Lung Cancer (NSCLC) Subcommittee

subcommittee leadership

Roy Herbst, MD, PhD (Chair) Yale Cancer Center	Julie Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ramaswamy Govindan, MD Washington University School of Medicine	Naiyer Rizvi, MD Columbia University Medical Center

subcommittee members

Robert A. Anders, MD, PhD Johns Hopkins University School of Medicine	Scott J. Antonia, MD, PhD Moffitt Cancer Center	Marianne Davies, NP Yale Cancer Center
Steven M. Dubinett, MD David Geffen School of Medicine at UCLA	Andrea Ferris LUNGevity	Leena Gandhi, MD, PhD Dana-Farber Cancer Institute
Edward Garon, MD David Geffen School of Medicine at UCLA	Matthew D. Hellmann, MD Memorial Sloan Kettering Cancer Center	Fred R. Hirsch, MD, PhD University of Colorado School of Medicine
Shakuntala Malik, MD National Cancer Institute, National Institutes of Health	Joel Neal, MD, PhD Stanford School of Medicine	Vassiliki Papadimitrakopoulou, MD The University of Texas MD Anderson Cancer Center
David L Rimm, MD, PhD Yale University School of Medicine	Sarah Sagorsky, PA Johns Hopkins University School of Medicine	Lawrence H. Schwartz MD Columbia University College of Physicians and Surgeons
Boris Sepesi, MD, FACS The University of Texas MD Anderson Cancer Center	Beow Yong Yeap, ScD Massachusetts General Hospital, Harvard Medical School